Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: Restoration of previously unpublished methodology
JournalBMJ Evidence-Based Medicine
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractPurpose: Trustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine's risks and benefits. However, several pivotal trial publications incompletely reported important methodological details and inaccurately described the formulation that the control arms received. Under the Restoring Invisible and Abandoned Trials initiative (RIAT), we aim to restore the public record regarding the content and rationale of the controls used in the trials. Methods: We assembled a cohort (five randomised controlled trials) described as placebo-controlled using clinical study reports (CSRs) obtained from the European Medicines Agency. We extracted the content and rationale for the choice of control used in each trial across six data sources: Trial publications, register records, CSR synopses, CSR main bodies, protocols and informed consent forms. Results: Across data sources, the control was inconsistently reported as containing aluminium adjuvant (sometimes with dose information). Amorphous aluminium hydroxyphosphate sulfate (AAHS) was not mentioned in any trial registry entry, but was mentioned in all publications and CSRs. In three of five trials, consent forms described the control as an 'inactive' substance. No rationale for the selection of the control was reported in any trial publication, register, consent form, CSR synopsis or protocol. Three trials reported the rationale for choice of control in CSRs: To preserve blinding and assess the safety of HPV virus-like particles as the safety profile of (AAHS) is well characterised'. Conclusions: The stated rationale of using AAHS control-to characterise the safety of the HPV virus-like particles-lacks clinical relevance. A non-placebo control may have obscured an accurate assessment of safety and the participant consent process of some trials raises ethical concerns. Trial registration numbers: NCT00092482, NCT00092521, NCT00092534, NCT00090220, NCT00090285. Copyright Author(s).
Keywordpaediatric infectious disease & immunisation
Randomized Controlled Trials as Topic--methods
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082520239&doi=10.1136%2fbmjebm-2019-111331&partnerID=40&md5=1b48054eb65a1b4a3995cf980415654f; http://hdl.handle.net/10713/12574
- Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?
- Authors: Petersen SB, Gluud C
- Issue date: 2020 Aug 6
- Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis.
- Authors: Schroll JB, Penninga EI, Gøtzsche PC
- Issue date: 2016 Aug
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
- Authors: Arbyn M, Xu L, Simoens C, Martin-Hirsch PP
- Issue date: 2018 May 9
- Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications.
- Authors: Jørgensen L, Gøtzsche PC, Jefferson T
- Issue date: 2020 Feb 28
- Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
- Authors: Garnock-Jones KP, Giuliano AR
- Issue date: 2011 Mar 26